Platinum(IV) Prodrug-1
Platinum (IV) Prodrug-1 is a Pt (IV) prodrug and selective TrxR1 inhibitor. Platinum (IV) Prodrug-1 induces ferroptosis (Ferroptosis) by depleting glutathione, accumulating intracellular lipid peroxides, and inactivating Glutathione peroxidase 4. Platinum (IV) Prodrug-1 triggers endoplasmic reticulum stress and immunogenic cell death via excessive accumulation of intracellular ROS. Platinum (IV) Prodrug-1 exhibits anticancer activity against both Cisplatin (HY-17394)-sensitive and Cisplatin-resistant triple-negative breast cancer cells. Platinum (IV) Prodrug-1 can be used for the research of triple-negative breast cancer.
For research use only. We do not sell to patients.
- Formula: C26H26Cl3F6N3O4Pt
- Molecular Weight:859.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
TrxR1 |
GPX4 |
In Vitro
Platinum(IV) Prodrug-1 (Compound 6b) (2.5-5 μM; 24 h) induces concentration-dependent mitochondrial membrane potential reduction and activates the mitochondrial apoptosis pathway in Cisplatin-resistant MDA-MB-231/CDDP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Platinum (IV) Prodrug-1 (7.2 mg/kg; intravenous injection; once every 2 days; for 21 consecutive days) exhibits potent in vivo anti-tumor activity in cisplatin-sensitive MDA-MB-231 triple-negative breast cancer (TNBC) xenograft-bearing BALB/c nude mice, with a tumor growth inhibition (TGI) rate of 73.8%, and no organ toxicity is observed[1].
Platinum (IV) Prodrug-1 (7.2 mg/kg; intravenous injection; once every 2 days; for 21 consecutive days) exhibits potent in vivo antitumor activity in cisplatin-resistant MDA-MB-231/CDDP triple-negative breast cancer (TNBC) xenograft-bearing BALB/c nude mice, with a tumor growth inhibition (TGI) rate of 66.3%, and no organ toxicity is observed[1].
Platinum (IV) Prodrug-1 (7.2 mg/kg; intravenous injection; once every 2 days; for 14 consecutive days) effectively inhibits lung metastasis of 4T1 triple-negative breast cancer (TNBC) cells in BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 4 weeks old, ~20 g, subcutaneous inoculation of 4T1 murine breast cancer cells)[1]
-
Dosage:7.2 mg/kg
-
Administration:i.v.; once every 2 days; 21 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 76.8%.
Showed no significant body weight loss in treated mice.
Increased proportions of tumor-infiltrating lymphocytes: CD3+ T cells (23.46%), CD3+CD4+ T cells (14.40%), and CD3+CD8+ T cells (8.85%).
Increased CD80+CD86+ dendritic cells (56.78%) relative to control.
Elevated serum levels of proinflammatory cytokines TNF-α, IFN-γ, and IL-6 significantly compared to other treatment groups.
Increased levels of the ICD marker CRT and ER stress marker CHOP in tumor tissue via immunofluorescence staining.
-
Animal Model:BALB/c nude (female, 4−5 weeks old, ~18 g, subcutaneous inoculation of MDA-MB-231 human breast cancer cells)[1]
-
Dosage:7.2 mg/kg
-
Administration:i.v.; once every 2 days; 21 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 73.8%.
Showed no significant body weight loss in treated mice.
Downregulated Ki67, TrxR1, and GPX4 expression significantly in tumor tissue relative to control and other treatment groups.
Showed no morphological alterations or adverse effects in major organs (heart, liver, spleen, lung, kidney) via H&E staining.
Chemical Information
-
Molecular Weight 859.94
-
Formula C26H26Cl3F6N3O4Pt
-
SMILES
O=C(CCCC(O[Pt]([NH3])(Cl)(Cl)([NH3])Cl)=O)N1C/C(C(/C(C1)=C/C2=CC(C(F)(F)F)=CC=C2)=O)=C\C3=CC=CC(C(F)(F)F)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)